SARS-COV-2
- 1 lab in 1 country
- 2 trials
- Funders: Chinese Academy of Medical Sciences Initiative for Innovative Medicine and 4 more
- Animals1
Outcomes
2Interstitial pneumonia
upin rhesus monkeys1
1 study
Interstitial pneumonia
upin rhesus monkeys1
SARS-COV-2 increases interstitial pneumonia in rhesus monkeys.
Animalsintratracheal infection
Age-related rhesus macaque models of COVID-19
Animal models and experimental medicine30 Mar 2020
Viral replication
upin rhesus monkeys1
1 study
Viral replication
upin rhesus monkeys1
SARS-COV-2 increases viral replication in rhesus monkeys.
Animalsnasopharyngeal, anal, lung14 days
Age-related rhesus macaque models of COVID-19
Animal models and experimental medicine30 Mar 2020
Trial sponsors
Company2 trialsPhase 31,400 people
Funding
13 grants since 2022National Institute on AgingUS$18.9mNational Institute of Allergy and Infectious DiseasesUS$1.8mNational Institute of Neurological Disorders and StrokeUS$1.6m
National Institute on AgingUniversity of Texas Hlth Science CenterUS$1.8m2023–2028
National Institute on AgingUniversity of RochesterUS$724.4k2022–2027
National Institute on AgingHarvard University D/b/a Harvard School of Public HealthUS$88.2k2023–2029
National Institute on AgingUniversity of MinnesotaUS$700.1k2022–2027
Induction and maintenance of SARS-CoV-2 mRNA vaccine-specific memory across tissues
National Institute of Allergy and Infectious DiseasesColumbia University Health SciencesUS$55.1k2023–2027
National Institute on AgingCleveland Clinic Lerner Com-cwruUS$780.7k2023–2028
Alzheimer’s Disease Related Biomarkers following SARS-CoV-2 Infection
National Institute on AgingNew York University School of MedicineUS$1.4m2022–2027
National Institute of Neurological Disorders and StrokeUniversity of Illinois at ChicagoUS$801.3k2024–2029
National Institute of Allergy and Infectious DiseasesBoston Children's HospitalUS$1.7m2025–2031
Long-term Neuropsychiatric Sequelae of SARS-CoV-2 Infection in Late Life
National Institute on AgingNorthern California Institute/res/eduUS$709.6k2023–2029